Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Offload AGs of Allegra and Plavix to Meiji Group
October 8, 2025
- NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
October 8, 2025
- Kissei Grants Linzagolix Rights to Searchlight in Canada
October 8, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
- Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen
October 8, 2025
- Japan Ethical Drug Sales Edge Up 0.4% in August: Crecon
October 8, 2025
- Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
- Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations
October 7, 2025
- Chugai CEO Lauds Sakaguchi’s Nobel-Winning Work
October 7, 2025
- Alfresa, Kidswell, and Others to Form JV for Biosimilar Production in Japan
October 7, 2025
- Gilead Opens Japan Facility to Support CAR-T Delivery
October 7, 2025
- Datroway Hits Key Goals in Global PIII Trial for TNBC: Daiichi Sankyo
October 7, 2025
- SymBio Kicks Off Global PIII Trial of Brincidofovir in Europe
October 7, 2025
- Keytruda Maintains No. 1 Spot for 24th Straight Month: Encise
October 7, 2025
- Takeda Pulls Plug on Cell Therapy Work after Strategy Review
October 6, 2025
- LEO Pharma Begins Promotional Activities for Spevigo in Japan
October 6, 2025
- Sanofi Files ITP Drug Rilzabrutinib in Japan
October 6, 2025
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
- Argenx Puts Japan at Core of Global Innovation Strategy
October 3, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…